ReviewNanobiomedicine
ZnO Nanoparticles: A Promising Anticancer Agent.
Review in Nanobiomedicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 138 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
138 citing papers in PubMed, 483 citations in OpenAlex.
- Sustainable nanomedicine from olive leaf waste: biosynthesized ZnONPs with mechanistic validation against hepatocellular carcinoma.RSC advances · 2026Article
- Green-SynthesizedBiomimetics (Basel, Switzerland) · 2026Article
- Tuning Anticancer Activity and Antimicrobial Response of ZnO Nanoparticles Through Halogenosilane Surface Modification.International journal of molecular sciences · 2026Article
- Insights into the antibacterial, antifungal, and antiparasitic activities of functionalized ZnO quantum dots.Scientific reports · 2026Article
- Evaluating the mechanisms and therapeutic potential of ZnO nanoparticles as selective anticancer agents for lung malignancies.Discover nano · 2026Review
- Eco-friendly synthesis and antibacterial evaluation of CuO, ZnO, and CuO-ZnO nanostructures supported by DFT and molecular docking.Discover nano · 2026Article
- Nanotechnology in Cancer Therapy: How Nanoparticles Are Shaping the Future of Personalized Treatment.ACS nano medicine · 2026Review
- Probiotic-derived EPS-ZnO nanoparticles: therapeutic potential in colorectal cancer gene regulation.Cancer cell international · 2026Article
- Article
- Eco-friendly synthesis of star-shaped Zn nanoparticles using Beta vulgaris peel extract and evaluation of their antibacterial, photocatalytic, and cytotoxic activities.Scientific reports · 2026Article
- Designing drug delivery systems: the impact of structural order and disorder for optimized therapeutic outcomes.Nanomedicine (London, England) · 2026Review
- Article
- Apoptosis-Mediated Anticancer Activity of Zinc Oxide Nanoparticles Derived and Characterized fromAnti-cancer agents in medicinal chemistry · 2026Article
- Biomimetic green synthesis of ZnO nanoparticles using Cheilocostus speciosus and Gardenia gummifera with comprehensive characterization and bioactivity assessment.Scientific reports · 2025Article
- Green synthesis of Cu-doped ZnO nanocomposites using Phytolacca Dodecandra root extract to improve photocatalytic and antibacterial activity and extend avocado shelf-life.Scientific reports · 2025Article
- Antiproliferative and apoptotic activity of a Zn(II) complex against cancer cells, both in vitro and in vivo.Discover oncology · 2025Article
- Pharmacological properties of Bergenia ciliata synthesized green zinc sulfide nanoparticles (ZnS-NPs) and zinc oxide nanoparticles (ZnO-NPs).Bioprocess and biosystems engineering · 2025Article
- Significance of Nano Transition Metal Complexes as Anticancer and Antibacterial Therapeutic Agents.International journal of molecular sciences · 2025Article
- Secret elixirs of nature: extract type shapes the phytochemical-mediated synthesis and anticancer potential of ZnO and FeScientific reports · 2025Article
- Biogenic ZnO Nanoparticles Synthesized byNanomaterials (Basel, Switzerland) · 2025Article
78 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanoparticles, with their selective targeting capabilities and superior efficacy, are becoming increasingly important in modern cancer therapy and starting to overshadow traditional cancer therapies such as chemotherapy radiation and surgery. ZnO nanoparticles, with their unique properties such as biocompatibility, high selectivity, enhanced cytotoxicity and easy synthesis, may be a promising anticancer agent. Zinc, as one of the major trace elements of the human body and co-factor of more than 300 mammalian enzymes, plays an important role in maintaining crucial cellular processes including oxidative stress, DNA replication, DNA repair, cell cycle progression and apoptosis. Thus, it is evident that an alteration in zinc levels in cancer cells can cause a deleterious effect. Research has shown that low zinc concentration in cells leads to the initiation and progression of cancer and high zinc concentration shows toxic effects. Zinc-mediated protein activity disequilibrium and oxidative stress through reactive oxygen species (ROS) may be the probable mechanism of this cytotoxic effect. The selective localization of ZnO nanoparticles towards cancer cells due to enhanced permeability and retention (EPR) effect and electrostatic interaction and selective cytotoxicity due to increased ROS present in cancer cells show that ZnO nanoparticles can selectively target and kill cancer cells, making them a promising anticancer agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.